What is Rapid Pathogen Screening?
Rapid Pathogen Screening, also known as RPS Diagnostics (RPS), is an emerging entity focused on the development, manufacturing, and marketing of cost-effective point-of-care (POC) tests designed for systemic infectious diseases and antibiotic stewardship. The company's flagship product, the FebriDx test, is a disposable, in-office diagnostic tool that utilizes a finger-stick blood sample. It is engineered to identify a clinically significant immune response and differentiate between bacterial and viral causes of fever in acute respiratory infections. With a high negative predictive value of 97%, FebriDx delivers results within 15 minutes, empowering clinicians with actionable insights during initial patient visits to guide antibiotic prescribing decisions and limit unnecessary use.
How much funding has Rapid Pathogen Screening raised?
Rapid Pathogen Screening has raised a total of $34.6M across 3 funding rounds:
Unspecified
$6.3M
Debt
$28M
Debt
$350K
Unspecified (2013): $6.3M with participation from Mallitz Investment Group
Debt (2014): $28M led by OrbiMed Advisors, LLC
Debt (2020): $350K supported by PPP
Key Investors in Rapid Pathogen Screening
OrbiMed Advisors, LLC
OrbiMed Advisors LLC is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. They support companies at various stages of development, from early-stage ventures to established organizations scaling solutions.
Mallitz Investment Group
The Mallitz Investment Group, LLC (MIG) is a family-backed investment firm focused on private, proprietary transactions, particularly in debt-oriented strategies. They implement institutional discipline in screening, due diligence, and monitoring investments, aiming to deliver institutional-level returns through risk-mitigated structures.
What's next for Rapid Pathogen Screening?
The recent major strategic investment positions Rapid Pathogen Screening for accelerated growth and market penetration. This capital infusion is expected to fuel further research and development, enhance manufacturing capacity, and expand the commercialization efforts for the FebriDx test. The company's focus on addressing the critical need for rapid, accurate diagnostics in infectious disease management aligns with current healthcare priorities, suggesting a strategic expansion into new markets and potential partnerships. The enterprise-level backing indicates confidence in RPS's technology and its potential to significantly impact public health by improving diagnostic accuracy and promoting responsible antibiotic use.
See full Rapid Pathogen Screening company page
